CD34+cells augment endothelial cell differentiation of CD14+endothelial progenitor cells in vitro by Krenning, G. et al.
  
 University of Groningen
CD34+cells augment endothelial cell differentiation of CD14+endothelial progenitor cells in
vitro
Krenning, G.; van der Strate, B. W. A.; Schipper, M.; Gallego y van Seijen, X. J.; Fernandes,
B. C. A.; van Luyn, M. J. A.; Harmsen, M. C.
Published in:
Journal of cellular and molecular medicine
DOI:
10.1111/j.1582-4934.2008.00479.x
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Krenning, G., van der Strate, B. W. A., Schipper, M., Gallego y van Seijen, X. J., Fernandes, B. C. A., van
Luyn, M. J. A., & Harmsen, M. C. (2009). CD34+cells augment endothelial cell differentiation of
CD14+endothelial progenitor cells in vitro. Journal of cellular and molecular medicine, 13(8B), 2521-2533.
https://doi.org/10.1111/j.1582-4934.2008.00479.x
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Introduction
Coronary artery disease and myocardial infarctions are the major
cause of death in the industrialized world (www.who.org). Current
treatments, such as percutaneous angioplasty and bypass surgery,
focus on the relieving of the ischaemia, reducing ongoing tissue
damage, rather than on tissue regeneration. This warrants investi-
gation into new strategies for the treatment of ischaemic diseases.
Regenerative medicine aims to maintain, improve or restore
tissue function by employing the bodies’ own regenerative mech-
anisms. An example is cell therapy, which is an experimental strategy
for the treatment of ischaemic diseases, such as myocardial
infarction. Herein, neovascularization induced by progenitor cells
is an essential factor and has been a topic of intense research over
the past decade. The rare CD34 stem cell is often designated as
the endothelial progenitor cell (EPC), as it contributes to repair of
vascular damage in vivo. However, incorporation of CD34 cells
into the neovasculature is limited [1–4]. We, and others, have
shown that in vivo neovascularization relies on a paracrine func-
tion of human CD34 cells, which involves recruitment of mono-
cytes, rather than actual incorporation [5, 6] among others.
In a mouse model of myocardial infarction, we have shown that
ischaemic tissue damage leads to the recruitment of bone marrow
derived progenitor cells and monocytes to the damaged site,
which is a prerequisite for repair. These bone marrow derived cells
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Abstract
Neovascularization by endothelial progenitor cells (EPC) for the treatment of ischaemic diseases has been a topic of intense research.
The CD34 cell is often designated as EPC, because it contributes to repair of ischaemic injuries through neovascularization. However,
incorporation of CD34 cells into the neovasculature is limited, suggesting another role which could be paracrine. CD14 cells can also
differentiate into endothelial cells and contribute to neovascularization. However, the low proliferative capacity of CD14 cell-derived
endothelial cells hampers their use as therapeutic cells. We made the assumption that an interaction between CD34 and CD14 cells
augments endothelial differentiation of the CD14 cells. In vitro, the influence of CD34 cells on the endothelial differentiation capacity
of CD14 cells was investigated. Endothelial differentiation was analysed by expression of endothelial cell markers CD31, CD144, von
Willebrand Factor and endothelial Nitric Oxide Synthase. Furthermore, we assessed proliferative capacity and endothelial cell function of
the cells in culture. In monocultures, 63% of the CD14-derived cells adopted an endothelial cell phenotype, whereas in CD34/CD14
co-cultures 95% of the cells showed endothelial cell differentiation. Proliferation increased up to 12% in the CD34/CD14 co-cultures
compared to both monocultures. CD34-conditioned medium also increased endothelial differentiation of CD14 cells. This effect was
abrogated by hepatocyte growth factor neutralizing antibodies, but not by interleukin-8 and monocyte chemoattractant protein-1 neu-
tralizing antibodies. We show that co-culturing of CD34 and CD14 cells results in a proliferating population of functional endothelial
cells, which may be suitable for treatment of ischaemic diseases such as myocardial infarction.
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also differentiate, to myofibroblasts and thus contribute to wound
healing [7]. Furthermore, the recruited monocytes were shown to
influence neovascularization and remodelling after myocardial
infarction, as depletion of these cells from the circulation resulted
in decreased neovascularization and impaired remodelling of the
myocardial infarction [8]. In vitro, we have shown that human
monocytes, i.e. CD14 cells, differentiate into functional endothe-
lial cells [9]. As a consequence of this ability, these CD14 cells
are often referred to as ‘early EPC’ [10], ‘colony forming unit-
endothelial cell (CFU-EC)’ [11, 12] or ‘endothelial-like cells’ 
[9, 13]. Thus, differentiated CD14 cells may contribute to neo-
vascularization in vivo and to remodelling of the infracted area.
These data suggest that both CD34 cells and CD14 cells
play a key role in the repair and regeneration in cardiovascular
and ischaemic diseases. We made the assumption that circulating
EPCs, i.e. CD34 cells, and CD14 cells interact during neovas-
cularization and that paracrine signalling of CD34 cells aug-
ments endothelial cell differentiation of the CD14 cells. We
examined the interaction between CD34 cells and CD14 cells
and the effect on endothelial cell differentiation and cell prolifera-
tion in vitro. To this end, these cells were co-cultivated and the
expression of endothelial cell markers was evaluated.
Additionally, the (paracrine) factors that drive the endothelial cell
differentiation and proliferation were investigated. Finally, the
functionality of the newly differentiated endothelial cells was
assayed in vitro.
Materials and methods
Cell isolation and culture
Peripheral blood mononuclear cells (pbMNC) were isolated from buffy
coats from healthy donors (Sanquin, Groningen, the Netherlands) using
density gradient centrifugation on lymphoprep (Nycomed Pharma,
Roskilde, Norway). CD34 cells were isolated by magnetic bead separation
and further purified by fluorescence-activated cell sorting (FACS) as
described previously [6]. Subsequently, monocytes, i.e. CD14 cells, were
isolated from the remaining MNC-fraction by magnetic bead separation as
described previously [9]. Flow cytometric analysis revealed an average puri-
ty of 98.4  1.2% (n  4) for isolated CD34 cells and 99.8  0.1% (n 
4) for isolated CD14 cells.
CD34 cells and CD14 cells were cultured either in monoculture or in
co-culture in ratios 1:10, 1:100 and 1:1000 (CD34 cells in CD14 cells,
respectively). Co-cultures were derived from one single donor to avoid
immunological mismatches. Cells were cultured in fibronectin/gelatin
[both 10 g/ml in phosphate-buffered saline (PBS)] coated wells, at a den-
sity of 50,000/cm2. Culture medium consisted of RPMI1640 supplement-
ed with foetal calf serum (both BioWhittaker, Verviers, Belgium), 5 U/ml
heparin (LEO Pharma, Ballerup, Denmark), 0.3 mg/ml L-glutamine (GIBCO
Products, Grand Island, NY, USA) 1% Penicillin/Streptomycin (Sigma, St.
Louis, MO, USA), 50 g/ml endothelial cell growth factor (ECGF, accord-
ing to Burgess et al. [14]), 10 ng/ml basic fibroblast growth factor (bFGF)
and 1 ng/ml vascular endothelial growth factor (VEGF)-A (both Peprotech,
Rockhill, NJ, USA). Culture medium was refreshed every third day.
Colony forming unit-endothelial cell assays
Isolated CD34 and CD14 cells were labelled using carboxyfluorescein
diacetate, succinimidyl ester (CFSE) (green) and CM-DiI (red), respective-
ly (both Molecular Probes, Eugene, OR, USA), according to manufactur-
er’s instructions. The labelled cells were mixed with the remaining autol-
ogous pbMNC-fraction and cultured as described above. After 7 days, flu-
orescent microscopic analysis was performed with a Leica DMRXA fluo-
rescent microscope (Leica Microsystems, Wetzlar, Germany) to determine
the morphological status of labelled CD34 and CD14 cells. After 14 days,
spindle-shaped cells originating from CFU-ECs were quantified. Part of
the CFU-ECs were fixed using 2% Glutar Aldehyde (Merck, Darmstadt,
Germany) at 4C for 24 hrs, and prepared for transmission electron
microscopy. In short, fixed samples were rinsed with a 6.8% sucrose
solution (pH 7.4) for 30 min. Samples were post-fixed using a 0.1 M
potassium hexacyanoferrate(II)trihidrate (K4Fe(CN)6·3 H2O; Merck) solu-
tion containing 1% osmiumtetroxide (OsO4) at 4C for 45 min. Next, the
samples were dehydrated with ethanol, embedded in EPON 812 (Serva
Feinbiochemica, Heidelberg, Germany), and polymerized at 60C for at
least 48 hrs. Ultrathin sections were cut on a Sorvall microtome (Sorvall,
Newton, CT, USA) and contrasted with uranyl acetate and lead citrate. The
ultrathin sections were analysed in a Phillips 201 transmission electron
microscope (Phillips, Eindhoven, The Netherlands) operated at 60 kV.
Endothelial cell marker analysis
After 3 weeks of culture, mono- and co-cultured cells were dissociated
by accutase treatment (PAA Laboratories, Pashing, Austria). Cells were
incubated with either phycocerythrin (PE)-conjugated mouse antibodies
to human (MaH) CD34 (1:10 in 2% bovine serum albumin [BSA]; BD
Biosciences, San Jose, CA, USA), PE-conjugated MaH CD14 (1:10 in 2%
BSA; IQ Products, Groningen, The Netherlands), fluorescien (FITC)-con-
jugated MaH VEGFR-2 (1:10 in 2% BSA; R&D Systems, Minneapolis,
MN, USA), MaH cMET (1:100 in 2% BSA; R&D Systems) followed by
FITC-conjugated rabbit antibodies to mouse IgG (1:100 in 2% BSA;
DakoCytomation, Glostrup, Denmark), PE-conjugated mouse antibodies
to human CD31 (1:10 in 2% BSA/PBS; IQ Products) or with PE-conju-
gated MaH CD144 (1:20 in 2% BSA/PBS; R&D Systems) at 4C for 30
min. Next, cells were washed using PBS to remove excess antibodies
and fixed using 2% paraformaldehyde in PBS at room temperature (RT)
for 10 min. Thereafter, the cells were permeabilized with 0.01% saponin
in PBS. Subsequently, cells were incubated with rabbit antibodies to
human (RaH) von Willebrand factor (vWF) (1:50; DakoCytomation) or
RaH endothelial cell nitric oxide synthesis (eNOS) (1:50; BD
Biosciences). Cells were washed twice with 2% BSA/PBS and incubated
with FITC-conjugated donkey antibody F(ab)2 fragments to rabbit IgG
(1:100 in 2% BSA/PBS; Jackson ImmunoResearch, Suffolk, UK) on ice
for 30 min. Cells were washed three times in 2% BSA/PBS and analysed
using a FACSCaliber system (BD Biosciences). Isotype-matched, PE-
conjugated nonsense antibodies and FITC-conjugated donkey antibody
F(ab)2 fragments to rabbit IgG were used as controls.
Cell proliferation
After 3 weeks, mono- and co-cultured cells were dislodged by accu-
tase treatment. Cytospots were made from 50,000 cells and fixed in
acetone at RT for 10 min. and post-fixed using 2% paraformaldehyde
© 2008 The Authors
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in PBS at RT for 30 min. Fixed cells were permeabilized using 0.5%
Triton X-100 at RT for 10 min. After permeabilization, cells were pre-
incubated with 3% BSA in PBS at RT for 10 min. Next, samples were
incubated with MaH Ki67 (1:50; DakoCytomation) at RT for 60 min.
After washing and incubation with RedX-conjugated donkey antibody
F(ab)2 fragments to mouse IgG (1:100; Jackson ImmunoResearch) at
RT for 30 min. Samples were mounted in citifluor AP1 (Agar Scientific,
Essex, UK) and examined by immunofluorescence microscopy using a
Leica DMRXA microscope and Leica Software (Leica Microsystems).
RedX-conjugated donkey antibody F(ab)2 fragments to mouse IgG
were used as controls.
Thrombin generation assays and sprout formation
To assess their endothelial cell function, cultured cells were assayed for
their ability to inhibit factor-3-dependent thrombin formation. To this end,
a Thrombin Generation Assay (HaemoScan, Groningen, The Netherlands)
was used. In brief, mono- and co-cultured cells were dissociated by accu-
tase treatment and replated at a density of 50,000 cells/cm2 on
fibronectin/gelatin-coated culture wells subsequently. After overnight cul-
ture, the culture medium was removed and replaced by fibrinogen-depleted
human plasma. During this incubation the intrinsic coagulation cascade is
activated. Thereafter, the clotting cascade was further activated by addition
of a mixture of 30 mM CaCl2 and phospholipids, which results in the gen-
eration of thrombin. Samples were taken at regular intervals and added to
ice-cold 25 mM TrisHCl to prevent any further thrombin generation. Finally,
the diluted samples were incubated with 3 mM thrombin substrate S2238.
Thrombin releases p-nitroaniline chromophore from the substrate, which
results in a change of colour. The change in colour was measured at 405
nm with 540 nm as reference wavelength in a microtitre plate reader
(BioRad, Hercules, VA, USA). A calibration curve of known thrombin con-
centrations was used to quantify the thrombin formation in the experimen-
tal samples. Human umbilical vein endothelial cells (HUVEC) and factor-3
positive vascular smooth muscle cells (VSMC) were used as negative and
positive controls, respectively.
The ability to form capillary-like sprouts was investigated using a
Matrigel Sprouting Assay (BD Biosciences). After 21 days of culturing,
monocultured and co-cultured cells were dissociated using accutase and
plated on Matrigel (BD Biosciences) coated wells at a density of 250,000
cells/cm2 and cultured in endothelial cell medium for an additional 24 hrs.
The formation of capillary-like structures was analysed using regular light
microscopy.
Cytokine and growth factor secretion
At days 0, 3, 7 and 21 of culture, culture medium was sampled. The con-
centration of cytokines angiopoietin (ANG)-2, interleukin (IL)-8, monocyte
chemoattractant protein (MCP)-1 and tumour necrosis factor- (TNF-) as
well as growth factors epidermal growth factor (EGF), bFGF, hepatocyte
growth factor (HGF), transforming growth factor-	 (TGF-	) and VEGFa
were determined using multiplex protein analysis by PerBio Sciences
(Cramlington, UK).
At day 3, total RNA was isolated from CD34 cell monocultures or
CD14 cell monocultures using an RNeasy Micro Kit (Qiagen, Valencia,
CA, USA) following manufacturer’s instructions. RNA integrity was deter-
mined by gel electrophoresis and RNA purity and concentration were
determined using Nanodrop equipment (Nanodrop Technologies,
Wilmington, NC, USA). Subsequently, 100 ng RNA was reverse transcribed
using a First Strand cDNA synthesis Kit (Fermentas UAB, Vilnius,
Lithuania). One micro litre cDNA was used for amplification in 384-well
microtitre plates in a TaqMan ABI7900HT cycler (Applied Biosystems,
Foster City, CA, USA) in a final reaction volume of 10 l containing 5 l
TaqMan universal PCR Master Mix (Applied Biosystems) and 0.5 l
primer/probe mix. Applied Biosystems ‘assay on demand’ primer/probe
sets were used to detect amplimers of 	-2-Microglobulin (	2M;
Hs99999907_m1), IL-8 (Hs00174103_m1), MCP-1 (Hs00234140_m1)
and HGF (Hs00300159_m1). Cycle threshold (CT) values for individual
reactions were determined using ABI Prism SDS 2.2 data processing soft-
ware (Applied Biosystems). To determine differences in gene transcripts
between CD34 cells and CD14 cells CT-values were normalized against
	2M using the 
CT-method (
CT(gene)  CT(gene) – CT(	2M)). To correct for
interassay variance, 
CT values were normalized against expression levels

















All cDNA samples were amplified in triplicate and RNA controls were includ-
ed to test for primer binding to genomic DNA. Differences of twofold high-
er or greater were considered to be biologically relevant.
Conditioned medium cultures
To assess the influence of paracrine factors produced during co-culti-
vation, conditioned medium cultures were performed. Briefly, CD14
cells were plated in fibronectin/gelatin-coated wells at a density of
250,000 cells/cm2. Every third day, culture medium was removed from
cells in mono- or in co-culture. Conditioned culture medium from dif-
ferent donors was pooled to reduce donor variation and sterilized by
filtration through a 0.2-m filter. Plated monocytes were cultured in
conditioned culture medium supplemented with excess neutralizing
goat antibodies to either human HGF, IL-8, MCP-1 or mock goat IgG
(all 200 ng/ml medium; all R&D Systems). Conditioned medium and
antibodies were refreshed every third day. After 21 days of culture,
cells were dissociated using accutase and stained for protein expres-
sion of CD31, vWF, CD144 and eNOS. Protein expression of these
endothelial cell markers was analysed by FACS analysis as described
above. Inhibition of endothelial cell differentiation by neutralizing anti-
bodies was calculated as the fraction of differentiation decrease by the
neutralizing antibodies in relation to the mock IgGs according to the
following equation: 
Relative differentiation inhibition (RDI) 
1  * 100%
Statistical analysis
Data are presented as mean  S.E. of the mean. Data in Gaussian distri-
bution are analysed by two-factor ANOVA followed by Tuckey post hoc analy-
sis. All other data were analysed using Mann-Whitney tests. Probabilities
lower than P  0.05 were considered to be statistically significant.
(SampleNAbs  CD14mock)
(Samplemock  CD14mock)
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Results
Phenotypes of CD34 cells and CD14 cells
CD34 cells and CD14 cells were isolated by magnetic bead iso-
lation from buffy coats from healthy donors. Subsequently,
CD34 cells were further purified by MoFlo cell sorting and
analysed by flow cytometry. The CD34 cells had an average 
purity of 98.4  1.2%. The isolated CD34 cells did not express
CD14, but showed slight expression of vascular endothelial
growth factor receptor-2 (VEGF-R2) (1.6  0.3%). The isolated
CD14 cells had an average purity of 99.8  0.1%. Part of the iso-
lated CD14 cells co-expressed of CD34 (0.96  0.18%), KDR
(85.6  4.8%), or the HGF receptor c-MET (88.2  2.8%). Of the
adherent CD34 or CD14 cells, neither cell fraction showed
expression of endothelial cell specific proteins (Table 1).
Colony forming unit-endothelial cells
Human pbMNC, containing fluorescently labelled CD34 cells-
and CD14 cells were cultured under angiogenic conditions.
Colonies had formed after 7 days of culturing (Fig. 1A).
Examination of the CFU-ECs by immunofluorescence microscopy
revealed that these CFU-ECs consisted mainly of CD14-derived
cells (Fig. 1B; red cells) and that CD34-derived cells (green cell)
co-localized with CD14-derived cells in these CFU-ECs (Fig. 1B).
Although CD34-derived cells were also found outside the CFU-
ECs, colonies lacking CD34-derived cells were almost never
observed. Analysis of outgrowth endothelial colonies by transmis-
sion electron microscopy also showed co-localization and cell–cell
contacts (arrows) of cells with progenitor cell morphology (Fig. 1C
and D; small-round cells) and cells with endothelial cell morphol-
ogy (elongated cells). Cultured cells with an endothelial-like 
morphology, i.e. spindle-shaped cells, were quantified after 14
days (Fig. 1E and F). By that time, the CFU-ECs had disappeared.
The frequency of spindle-shaped cells was significantly higher 
in the CD14 monocultures and in all CD34/CD14 co-cultures
than in the CD34 monoculture (20–32% versus 0.5%, respec-
tively, P  0.01). Spindle-shaped cells originated mainly from the
CD14 cell fraction (over 85%; Fig. 1D; white bars), whereas the
CD34 cells (black bars) hardly contributed to the total amount of
spindle-shaped cells. The number of spindle-shaped cells did not
differ between the CD14 monocultures and the CD34/CD14
cells in co-culture.
Endothelial cell marker expression
Protein expression of endothelial cell markers was determined by
immunofluorescent stainings (Fig. 2A and B) and FACS analysis
for CD14, CD31, VEGFR-2, vWF, CD144 and eNOS (Fig. 2C and D
and Table 2). CD34 cells in monoculture hardly ever expressed
endothelial cell markers. Although over 30% of CD34 cells did
express CD31 (Table 2), co-expression of CD31 and vWF was
almost never observed. In fact, only 6–9% of the CD34 cells
showed signs of endothelial cell differentiation by the combined
expression of either CD31 and vWF or CD144 and eNOS. In con-
trast, CD14 cells in monoculture efficiently differentiated into an
endothelial cell phenotype. CD14 cell-derived endothelial cells
lost their expression of monocyte marker protein CD14, which
decreased from 99.80  0.10% (day 1) to 12.53  2.54% (day
21; Table 2). Over 60% of the CD14 cells had acquired a
CD31vWF phenotype and a CD144eNOS phenotype (Fig. 2C).
Interestingly, endothelial cell differentiation was significantly
increased in all the co-cultures, where over 85% of cells acquired
the CD31vWF phenotype (P  0.01 versus CD14 cells) and
over 90% of cells acquired the CD144eNOS phenotype (P 
0.001 versus CD14 cells). Expression of VEGFR-2 was present
on the CD14 cells at the start of culture and did not change dur-
ing the mono- or co-culture time (Table 2). Expression of all
endothelial cell markers by co-cultured cells was not different
from HUVEC and was similar in all co-cultures (Fig. 2C).
Cell proliferation
Proliferation of cultured cells was assessed by staining of nuclear
antigen Ki67 at day 21 (Fig. 3A and B). In the monocultures 
containing either CD34 cells or CD14 cells, no or limited prolifer-
ation was observed (Fig. 3C). CD34 monocultures did not 
proliferate at all, and only 1.13  0.24% of the CD14 cells in mono-
culture stained positive for Ki67. The co-cultured cells in the ratio of
CD34 (1:100) CD14 and CD34 (1:1000) CD14 showed significantly
higher proliferation rates (10.70  1.02% and 9.20  1.14%,
respectively, P  0.01) than the CD14 cells in monoculture. The co-
culture of CD34 (1:10) CD14 also showed higher proliferation rates
(6.01  1.37%, P  0.05) than the CD14 cells in monoculture did,
but proliferation in the CD34 (1:10) CD14 co-culture was lower than
in the other two co-cultures (P  0.05). At no time, proliferation was
observed in the monocultures (data not shown).
© 2008 The Authors
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CD34 CD14
CD14 %-positive cells 0.0 99.80  0.10%
CD34 %-positive cells 98.40  1.20% 0.96  0.18%
c-MET %-positive cells ND 88.21  2.81%
VEGF-R2 %-positive cells 1.60  0.30% 85.60  4.80%
CD31 %-positive cells 0.0 87.28  6.29%
vWF %-positive cells 0.0 0.91  0.37%
CD144 %-positive cells 0.0 1.32  0.66%
eNOS %-positive cells 0.0 1.20  1.04%
Table 1 Protein expression of adherent CD34 or CD14 cells (day 1)
Data are presented as mean  S.E.M. of at least three independent
experiments. ND  Not determined.
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Endothelial cell function
To assess the functionality of the cultured cells, their ability to prevent
factor 3-dependent thrombin formation was determined (Fig. 4A).
The formation of thrombin by HUVEC was 73.5  9.5 mU/ml,
whereas thrombogenic VSMC showed a 10-fold increase in
thrombin formation (733.6  203.8 mU/ml, P  0.01 versus
HUVEC). Co-cultured CD34 cells and CD14 cells produced
lower amounts of thrombin than VSMC (85–116 mU/ml, P 
0.01). Moreover, thrombin generation by co-cultured cells was not
different from HUVEC. Although CD14-derived endothelial cells
in monoculture tended to generate more thrombin than HUVEC
(175.5  36.3 mU/ml, P  0.10), no significant difference was
found. Furthermore, the thrombin generation by CD14 cells in
monoculture was not different from the thrombin generation
observed by the co-cultured cells.
Cells from CD14 monocultures or CD34/CD14 co-cultures
were plated on Matrigel-coated wells plates in order to investigate
their ability to form capillary like structures. Freshly isolated
CD14 cells did not form any capillary-like structures on Matrigel
(data not shown). Both monocultured CD14 cells as well as 
co-cultured CD34/CD14 cells formed branched structures on
Matrigel (Fig. 4B). There was no difference found in the number of
branches between CD14 cell monocultures or CD34/CD14
co-cultures. Nor did addition of HGF potentiate the formation of
capillary-like structures.
© 2008 The Authors
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Fig. 1 Formation of endothelial outgrowth
colonies and cells. Peripheral blood MNC
form colony forming unit-endothelial cells
(CFU-ECs) after angiogenic stimulation (A).
Within these colonies, CD34 cells (green
cell) and CD14 cells (red cells) co-localize
(B). At the sites of endothelial cell forma-
tion, cell–cell contacts (arrows) are formed
between cells with progenitor cell- (small
round) and endothelial cell (spindle-
shaped) morphology (C). At day 14, spin-
dle-shaped cells (D, arrows) originating
from these CFU-ECs are mainly derived
from the CD14 cells (E).
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Cytokine and growth factor secretion
Culture medium from CD34 cells and CD14 cells in monocul-
ture and the CD34 (1:100) CD14 co-culture were analysed for the
presence of EGF, bFGF, HGF, TGF-	1 and VEGF-A, as well as for the
cytokines ANG-2, IL-8, MCP-1 and TNF-. Basic FGF (189.9 
28.8 pg/ml), VEGF- (271.0  40.2 pg/ml) were present in the
culture medium. Background levels of TGF-	1 (2.38  0.13
ng/ml) and TNF- (28.3  9.8 pg/ml) were detected whereas EGF
was not detected. Although the levels of these growth factors and
cytokines varied slightly, no significant changes were detected in
their protein levels during the 21-day culture period (see online
data supplement). ANG-2 was also not present in the culture
medium, but a concentration of 33.8  8.4 pg/ml was detected in
the CD34 (1:100) CD14 co-culture at day 3. At this time, concen-
tration of ANG-2 was higher in the co-culture than in both mono-
cultures (P  0.001), where ANG-2 protein was not detected.
Although ANG-2 protein was detected in the CD34 and CD14
monocultures after 7 days (6.7  6.7 pg/ml and 3.7  3.7 pg/ml,
respectively), ANG-2 concentration in the CD34 (1:100) CD14 
co-culture tended to be higher throughout the 21-day culture period
(P  0.10; see online data supplement).
Background levels of HGF (40.3  5.8 pg/ml), IL-8 (289.9 
174.9 pg/ml) and MCP-1 (105.4  55.2 pg/ml) were detected at
the start of culture. In contrast to the growth factors and cytokines
described above, significant increases in the concentrations of
these factors were observed (Fig. 5). The concentration of HGF
increased most rapidly in the CD34 monoculture, where HGF
concentration reached 11,202  5421 pg/ml (270-fold
increase) at day 3 (Fig. 5A). By then, the concentration of HGF pro-
tein in the CD34 monoculture was significantly higher than in the
CD14 monoculture (405.9  68.4 pg/ml, P  0.05) and the
CD34 (1:100) CD14 co-culture (408.7  73.5 pg/ml, P  0.05).
Concentrations of HGF protein in the CD14 monoculture and in
the CD34 (1:100) CD14 co-culture also increased during culture.
HGF concentration reached a maximum of over 10,000 pg/ml in all
cultures at day 21.
Concentrations of IL-8 and MCP-1 also showed a more rapid
increase in the CD34 monoculture compared to the CD14
monoculture and the CD34 (1:100) CD14 co-culture. At day 3, the
© 2008 The Authors








CD14 %-positive cells ND ND 12.53  2.54 ND ND ND
VEGF-R2 %-positive cells 88.27  1.16 ND 94.00  3.62 87.27  2.72 88.74  3.16 83.49  3.94c
(rMFI) (100  12.16) (91.86  12.60) (102.01  1.31) (105.61  2.31) (89.99  12.42)
CD31 %-positive cells 98.96  0.81# 34.28 63.84  8.28† 90.01  0.78# 95.10  2.36# 96.39  1.21#
(rMFI) (100  53.04) (362.47) (145.61  66.41) (177.37  13.38) (195.51  36.74) (197.87  8.85)
vWF %-positive cells 98.30  0.37# 9.07 65.29  7.09# 92.25  0.02# 89.70  8.51 95.87  1.77#
(rMFI) (100  38.67) (93.83) (93.48  0.17) (56.07  5.08) (75.00  39.15) (64.72  5.23)
CD144 %-positive cells 98.04  0.11 8.45 78.96  2.51 94.99  1.50 93.20  9.76 91.65  4.40
(rMFI) (100  13.36) (320.45) (219.33  84.60) (114.33  17.44) (126.05  23.76) (112.19  16.62)
eNOS %-positive cells 99.22  0.56# 6.43 61.24  3.89# 95.25  1.09# 84.08  10.80# 82.93  12.12#
(rMFI) (100  18.16) (182.71) (137.32  28.79) (98.46  9.06) (108.50  19.64) (92.07  8.81)
Table 2 Protein expression of endothelial cell specific markers (day 21)
Data are presented as mean  S.E.M. of at least three independent experiments.
Relative mean fluorescent intensity (rMFI) was calculated as follows: rMFI  (MFIsample/MFIHUVEC)*100%.
ND  not determined.
*n  1; †P  0.05 versus HUVEC and #P  0.05 versus CD14.
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Fig. 2 Endothelial cell differentiation of
CD14 cells. Monocultured and co-cul-
tured CD14 cells expressed CD31, vWF,
CD144 and eNOS after 21 days in culture.
Immunofluorescent stainings show co-
expression of CD31 and vWF (A) as well
as CD144 and eNOS (B) by cells in CD34
(1:100) CD14 co-culture. FACS analysis
showed that co-cultured cells had
increased percentages of cells that had
acquired the CD31vWF (C) and the
CD144eNOS phenotype (D). **  P 
0.01 versus CD14, ***  P  0.001 
versus CD14
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concentration of IL-8 in the CD34 monoculture was 25,277 
6474 pg/ml (240-fold increase). Increases in IL-8 concentra-
tions were also observed in the CD14 cell monocultures and in
the CD34 (1:100) CD14 co-cultures (Fig. 5B). Although these
increases started later than in the CD34 monocultures, concen-
trations of IL-8 increased even further. At day 7, concentrations of
IL-8 did not differ between CD14 monocultures and CD34
(1:100) CD14 co-cultures and reached concentrations of 788,455 
460,545 pg/ml (2700-fold increase). The MCP-1 protein con-
centration in CD34 monocultures was 32,853  5549 pg/ml
(310-fold increase) at day 3 and tended to be higher than 
MCP-1 concentrations in the CD14 monocultures (294.1  34.0
pg/ml, P  0.10) and CD34 (1:100) CD14 co-cultures (537.8 
140.6, P  0.10, Fig. 5C). Similar to IL-8 protein concentration,
the MCP-1 concentration in the CD14 monocultures and the
CD34 (1:100) CD14 co-cultures increased more slowly, but
reached higher levels (108,211  47,400 pg/ml and 152,132 
32,371 pg/ml, respectively). Concentrations of MCP-1 remained
high in all cultures throughout the 21-day culture period, but did
not differ between the cultures at day 21.
To examine if differences in protein concentrations of HGF, 
IL-8 and MCP-1 were related to differences in gene expression
between CD34 cells and CD14 cells in monoculture, we per-
formed transcriptome analysis (Fig. 5D). At day 3 of culture,
CD34 cells in monoculture had a higher gene transcript level for
both MCP-1 (9-fold) and HGF (7-fold) compared to CD14 cells in
monoculture, but there was no biologically relevant difference in
gene expression of IL-8 (2-fold).
Conditioned medium cultures
To assess the effects of paracrine factors, CD14 cells were cul-
tured in the presence of conditioned culture media. Thereafter,
expression of endothelial cell markers CD31, vWF, CD144 and
eNOS was assessed by FACS analysis. Endothelial cell differentia-
tion of monocultured CD14 cells was approximately 63% (Fig. 6A
and B) and did not change by addition of conditioned medium
from CD14 cells. In fact, the co-expression of CD144 and eNOS
was decreased to approximately 40% (P  0.01; Fig. 6B). In con-
trast to the CD14 cells conditioned medium, exposure to condi-
tioned media from either CD34 cells in monoculture, or
CD34/CD14 co-cultures, significantly increased endothelial cell
differentiation by CD14 cells (Fig. 6A and B). Co-expression of
endothelial cell markers CD31 and vWF increased from 63% for
CD14 cells in monoculture to over 95% in all the CD34 cells-
derived conditioned media (Fig. 6A; P  0.05). Similarly, the 
co-expression of endothelial cell markers CD144 and eNOS
increased from 63% for CD14 cells in monoculture to over 95% in
all the CD34 cells-derived conditioned media (Fig. 6B; P  0.001).
Neutralizing antibodies to HGF, IL-8 and MCP-1 were added to
the conditioned medium in order to determine their influence on
the increased endothelial cell differentiation. Neutralizing antibod-
ies to HGF reduced the effect of the conditioned culture media by
30–60% (Fig. 6C and D). Co-expression of endothelial cell mark-
ers CD31 and vWF was reduced by over 30% (P  0.05) both in
the CD34 and in the CD14 cells conditioned medium (Fig. 6C).
In contrast, HGF neutralizing antibodies added to CD14 cell con-
ditioned medium did not decrease co-expression of CD144 and
eNOS (P  0.24). Co-expression of CD144 and eNOS, however,
was reduced by approximately 50% when HGF neutralizing anti-
bodies were added to CD34/CD14 cell conditioned media (P 
0.05; Fig. 6D). A trend for decreased co-expression of CD144 and
eNOS was found when HGF neutralizing antibodies were added to
CD34 cells conditioned media (P  0.057), but did not reach
statistical significance. Addition of neutralizing antibodies to either
IL-8 or MCP-1 did not alter the co-expression of CD31 and vWF
and CD144 and eNOS (see online data supplement).
Addition of recombinant human HGF to CD14 cells in mono-
culture increased endothelial cell differentiation of CD14 cells, as
determined by co-expression of CD31 and vWF (Fig. 6E). The
increase in endothelial cell differentiation caused by the addition of
HGF was dose-dependent and had an EC50 of 11.09  2.12 ng/ml.
Discussion
Current gold standard cardiovascular therapies, such as percuta-
neous angioplasty and stenting, focus on the prevention of acute
and ongoing tissue damage by relieve of the ischaemia, rather
than on tissue regeneration. Therefore, tissue regeneration by
stem cell therapy is a promising new treatment strategy to treat
ischaemic diseases, such as myocardial infarction. However, cell
therapy strategies that use peripheral blood derived progenitor
cells as a source of EPCs have been hampered by low cell num-
bers, lack of cell proliferation and the absence of cellular contribu-
tion to the neovasculature. In this study, we have shown that (1)
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Fig. 3 Cell proliferation of CD14 cells. Cell proliferation was almost
never observed in monocultured CD14 cells (A), but was observed in
co-cultured cells (CD34 (1:100) CD14; B). *  P  0.05 versus CD14,
**  P  0.01 versus CD14, and ***  P  0.001 versus CD14.
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Fig. 4 Endothelial cell function of differenti-
ated CD14 cells. Endothelial cell function
was determined as the ability to inhibit
thrombin formation in vitro and the ability to
form capillary-like sprouts. Human umbilical
vein endothelial cells (HUVEC) are able to
inhibit the factor-3 dependant formation of
thrombin, whereas factor-3 positive smooth
muscle cells show high amounts of throm-
bin formed. Differentiated endothelial cells
derived from CD14 cells or CD34/CD14
co-cultures both inhibited thrombin forma-
tion (A). After 3 weeks in mono- or co-cul-
ture, CD14 derived endothelial cells had
the ability to form capillary-like sprouts on
Matrigel (B). ‡  P  0.10 versus HUVEC.
Fig. 5 Growth factor and cytokine secretion. Production and secretion of hepatocyte growth factor (HGF), IL-8 and MCP-1 by cells in monoculture or
in CD34 (1:100) CD14 co-culture. CD34 cells showed a more rapid increase in protein concentrations of HGF (A), IL-8 (B) and MCP-1 (C) compared
to CD14 monocultures or CD34 (1:100) CD14 co-culture. Gene transcript analysis for IL-8, MCP-1 and HGF showed higher transcript availability for
MCP-1 and HGF in the CD34 cell cultures. No difference in transcript availability was found for IL-8 between the CD34 cell and CD14 cell mono-
cultures. ‡  P  0.10 versus CD14 and CD34 (1:100) CD14, *  P  0.05 versus CD14 and CD34 (1:100) CD14.
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Fig. 6 CD34 cell-derived hepatocyte growth factor (HGF) augments endothelial cell differentiation of CD14 cells. Culturing CD14 cells in CD34-, or
CD34/CD14 conditioned media resulted in increased co-expression of CD31 and vWF (A) and CD144 and eNOS (B) compared to CD14 monocul-
tures or CD14 conditioned medium. Increase in endothelial marker expression was partially inhibited by neutralizing antibodies to HGF 
(C: CD31vWF and D: CD144eNOS). Addition of recombinant HGF to CD14 monocultures increased endothelial marker expression in a dose-
dependent manner (E). ‡  P  0.10 versus CD14, *  P  0.05 versus CD14, **  P  0.01 versus CD14, and ***  P  0.001 versus CD14.
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culturing human pbMNC under angiogenic conditions the forma-
tion of CFU-ECs in which CD34-derived cells and CD14-derived
cells co-localize, (2) the interaction between CD34-derived cells
and CD14-derived cells results in increased endothelial cell dif-
ferentiation of the CD14-derived cells in a paracrine and HGF-
dependent manner and (3) results in the generation of a functional
and proliferating endothelial cell population in vitro.
Although the CD34 stem cell has been regarded as the
archetype EPC, its cellular incorporation into the neovasculature
is hardly observed [2–4]. In fact, there is a growing body of lit-
erature showing that endothelial-like cells of monocytic (i.e.
CD14) origin influence neovascularization [6, 15–19]. We have
previously shown that monocyte depletion results in reduced
neovascularization of ischaemic areas after myocardial infarc-
tion [8]. Furthermore, data from both animal experiments and
clinical trials suggest that the CD34 cell augments neovascu-
larization and endothelial cell differentiation in a paracrine man-
ner, rather than by incorporation into the neovasculature [4–6,
20–24]. In addition, Bonello et al. reported increased numbers
of circulating CD14 cells after angioplasty-induced endothelial
cell damage [25]. These circulating CD14 cells may be mobi-
lized by increased levels of HGF after angioplasty [26] and help
to repair the injured endothelium [16, 27] by mechanisms
described here.
Here we aimed to investigate the interaction between CD34
cells and CD14 cells in vitro. We have shown that the culture of
pbMNC results in a co-localization of CD34-derived cells and
CD14-derived cells (Fig. 1). Similarly, Yoon et al. showed that
early endothelial cell outgrowth colonies comprised of CD14
monocytic cells and CD14 cells [19]. As shown in Fig. 1, we pos-
tulate that the CD14 cells observed by Yoon et al., are in fact
CD34-derived cells. Complementary, Rohde et al. in a recent
study showed that interaction of CD14 cells with T lymphocytes
was accountable for the formation of these CFU-ECs in vitro [28].
However, the influence of T lymphocytes on endothelial cell differ-
entiation was not investigated. This suggests that T cells, in com-
bination with CD14 cells and CD34 cells form a microenviron-
ment, i.e. the CFU-ECs, in which differentiation of primitive CD14
cells towards an endothelial cell lineage is instructed.
In agreement with our finding that co-cultivation of CD34
cells and CD14 cells results in increased endothelial cell differen-
tiation in vitro (Fig. 2), Yoon et al. showed increased endothelial
cell differentiation in vitro and increased progenitor cell incorpora-
tion into the neovasculature when a mixture of CD14 cells and
CD34 cells were co-injected into ischaemic hind limbs of nude
mice [19]. Similarly, in vivo co-localization of CD14 cells and
CD34 cells at sites of active neovascularization and endothelial
cell differentiation was reported by Anghelina et al. and Moldovan
et al. [15, 29, 30].
Co-cultivation did not only result in increased expression 
of endothelial cell markers by CD14 cells, but also in gain of
endothelial cell functionality. In concurrence with the work of
Smadja et al. who reported that umbilical cord EPC have anticoag-
ulant effects [31], we show that CD14 cell-derived endothelial
cells actively inhibit thrombin formation in an in vitro coagulation
assay (Fig. 4) and thus can influence haemostasis.
Besides increased differentiation of functional endothelial
cells, we show that co-cultivation of CD34 cells and CD14 cells
results in increased proliferation of the CD14 cells (Fig. 3). In
agreement with other studies, we found that monocultured
CD14 cells proliferate only scarcely [9, 13, 32–34]. However,
when cultured in the presence of CD34 cells, proliferation
increased to approximately 10% at week 3 indicating differentia-
tion of long-lived CD14 cell-derived endothelial cells. Although
higher levels of proliferation by CD14 cells in pre-differentiation
cultures have been described [35–37], only few reports describe
the differentiation of a functional and proliferating endothelial cell
population originating from CD14 cells. Our finding that func-
tional and proliferating endothelial cells can be differentiated from
CD14 cells, corroborates the findings of Elsheikh et al. and
Romagnani et al. [38, 39].
To assess whether the increase in endothelial cell differentia-
tion and proliferation depends on cell–cell adhesions, we per-
formed differentiation experiments using conditioned culture
media from CD34 and CD14 monocultures. Although cell–cell
adhesions were identified between cells with an endothelial cell-
and with progenitor cell-morphology (Fig. 1), CD34 cells condi-
tioned culture media displayed a similar increase in endothelial cell
differentiation as seen in CD34/CD14 cells in co-culture (com-
parison Figs 2 and 6). Therefore, we conclude that CD34 cells
influenced the differentiation of CD14 cells in a paracrine man-
ner. This paracrine effect of CD34 cells has been suggested pre-
viously. More precise, we and others have described the secretion
of pro-angiogenic factors, such as MCP-1, IL-8, VEGF and bFGF
[4–6, 20–24], by CD34 cells both in vitro and in vivo, rather than
endothelial cell differentiation and incorporation into the neovas-
culature by that same cell type.
Analysis of conditioned culture media revealed large increases
in secreted IL-8, MCP-1 and HGF during a 3-week culture period.
Notably, the gene transcripts of these factors were present at a
higher level in CD34 cells than in CD14 cells, and the extracel-
lular concentrations of these pro-angiogenic factors increased
faster in the CD34 cells culture media than in CD14 cell condi-
tioned media or the CD34/CD14 co-culture media (Fig. 5). This
suggests that these factors are actively taken up by the CD14 cells
and used during downstream signalling cascades. Therefore, we
investigated the effects of these factors on endothelial cell differen-
tiation by CD14 cells using neutralizing antibodies against IL-8,
MCP-1 and HGF. IL-8 and MCP-1 have been described as angio-
genic cytokines. In this context, IL-8 and MCP-1 were associated
with the recruitment and migration of CD14 cells [6, 29, 40–43],
CD14 cell adhesion [16], growth factor secretion [44–46] and
endothelial cell proliferation [47]. Although IL-8 and MCP-1 are
involved in the induction of angiogenesis and cell recruitment, we
did not observe inhibition of endothelial cell differentiation by IL-8
nor MCP-1 neutralizing antibodies in vitro (see online data supple-
ment). This suggests that IL-8 and MCP-1 act at a different level on
CD14 cells during neovascularization, other than endothelial cell
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differentiation. In contrast, neutralizing antibodies to HGF did
decrease endothelial cell differentiation by CD14 cells and addi-
tion of HGF to CD14 cells in monoculture did increased endothe-
lial cell differentiation of these cells in a dose-dependent manner
(Fig. 6). Our observation in vitro appears to be supported by in vivo
data of Cai et al. who showed that HGF is an obligatory molecule
for revascularization of ischaemic tissue [48]. Furthermore,
Bordoni et al. have shown that hepatocyte-conditioned medium
was able to influence endothelial cell differentiation by EPC in vitro
[49]. These findings support our finding that indeed HGF is
involved in endothelial cell differentiation by CD14 cells.
In summary, we show that co-cultivation of CD34 cells and
CD14 cells results in increased differentiation of human CD14
cells towards functional and proliferating endothelial cells in vitro.
The increased differentiation and proliferation were dependent on
paracrine signalling through HGF, rather than on cell–cell contacts.
Taken together, the combination of CD14 cells and CD34 cells
yields a proliferating population of endothelial cells that may be a
suitable cell source that can be applied as cell therapeutic for treat-
ment of cardiovascular diseases, and can augment therapeutic
neovascularization in various disease models.
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